Recent Finacing
Recent Raise
Yellowstone Biosciences is an Oxford‑based biotech developing soluble bispecific T‑cell receptor engagers for HLA Class II peptides, leveraging a 10,000‑sample AML biobank to target AML and other HLA‑II cancers.
Recent Investors
Total Raised
Funding round
Investor
See the team members at Yellowstone Biosciences.
